Sepracor Inc. said Thursday it completed the purchase of a bulk-drugmanufacturing facility that's under construction near Halifax, NovaScotia.Sepracor paid about $2.6 million for the plant, which was sold byPharmaglobe Manufacturing Ltd. of Windsor, Nova Scotia. Sepracor ofMarlborough, Mass., plans to use the plant for good manufacturingpractices (GMP) manufacturing of single-isomer drugs and drugintermediates.Tim Barberich, Sepracor's chief executive officer, told BioWorld thatPharmaglobe invested about $6.5 million in the plant and another $8million will be needed before the plant is operational, which isexpected around the end of the year."The capability to manufacture bulk drugs in our own GMP facility hasbeen a long-standing aim of our chiral pharmaceutical strategy," saidRobert Bratzler, executive vice president and general manager ofSepracor's chiral chemicals business. "At this facility we intend toproduce single-isomer forms of chiral drugs and drug intermediates ona large scale, and to scale-up our proprietary processes as ourpharmaceutical customers' drugs progress through the developmentpipeline." _ Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.